BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 17050900)

  • 1. Counseling plus buprenorphine-naloxone for opioid dependence.
    Gorelick DA
    N Engl J Med; 2006 Oct; 355(16):1736; author reply 1736-7. PubMed ID: 17050900
    [No Abstract]   [Full Text] [Related]  

  • 2. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence.
    Fiellin DA; Pantalon MV; Chawarski MC; Moore BA; Sullivan LE; O'Connor PG; Schottenfeld RS
    N Engl J Med; 2006 Jul; 355(4):365-74. PubMed ID: 16870915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.
    Weiss RD; Potter JS; Fiellin DA; Byrne M; Connery HS; Dickinson W; Gardin J; Griffin ML; Gourevitch MN; Haller DL; Hasson AL; Huang Z; Jacobs P; Kosinski AS; Lindblad R; McCance-Katz EF; Provost SE; Selzer J; Somoza EC; Sonne SC; Ling W
    Arch Gen Psychiatry; 2011 Dec; 68(12):1238-46. PubMed ID: 22065255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment completion on an inpatient detoxification unit: impact of a change to sublingual buprenorphine-naloxone.
    Soeffing JM; Rastegar DA
    J Subst Abuse Treat; 2007 Dec; 33(4):401-4. PubMed ID: 17400414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In brief: Buprenorphine/naloxone (Zubsolv) for opioid dependence.
    Med Lett Drugs Ther; 2013 Oct; 55(1427):83. PubMed ID: 24129113
    [No Abstract]   [Full Text] [Related]  

  • 6. Cocaine use reduction with buprenorphine (CURB): rationale, design, and methodology.
    Mooney LJ; Nielsen S; Saxon A; Hillhouse M; Thomas C; Hasson A; Stablein D; McCormack J; Lindblad R; Ling W
    Contemp Clin Trials; 2013 Mar; 34(2):196-204. PubMed ID: 23159524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Buprenorphine + naloxone: new combination. Opiate dependence: no proof of reduced risk of self-administered injection.
    Prescrire Int; 2007 Dec; 16(92):232-5. PubMed ID: 18087797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Substitution therapy with buprenorphine to pregnant women with opioid dependency].
    Olofsson MJ; Ege PP
    Ugeskr Laeger; 2003 Sep; 165(38):3605. PubMed ID: 14556389
    [No Abstract]   [Full Text] [Related]  

  • 9. Buprenorphine and naloxone interactions in opiate-dependent volunteers.
    Mendelson J; Jones RT; Fernandez I; Welm S; Melby AK; Baggott MJ
    Clin Pharmacol Ther; 1996 Jul; 60(1):105-14. PubMed ID: 8689806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence.
    Mammen K; Bell J
    Expert Opin Pharmacother; 2009 Oct; 10(15):2537-44. PubMed ID: 19708849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opioid dependence.
    Praveen KT; Law F; O'Shea J; Melichar J
    Am Fam Physician; 2012 Sep; 86(6):565-6. PubMed ID: 23062049
    [No Abstract]   [Full Text] [Related]  

  • 12. The impact of community pharmacy dispensing fees on the introduction of buprenorphine - naloxone in Australia.
    Winstock AR; Lea T; Ritter A
    Drug Alcohol Rev; 2007 Jul; 26(4):411-6. PubMed ID: 17564877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abstinence-orientated buprenorphine replacement therapy for young adults in out-patient counselling.
    Kornør H; Waal H; Ali RL
    Drug Alcohol Rev; 2006 Mar; 25(2):123-30. PubMed ID: 16627301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Injection of buprenorphine and buprenorphine/naloxone tablets in Malaysia.
    Vicknasingam B; Mazlan M; Schottenfeld RS; Chawarski MC
    Drug Alcohol Depend; 2010 Sep; 111(1-2):44-9. PubMed ID: 20478668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users.
    Alho H; Sinclair D; Vuori E; Holopainen A
    Drug Alcohol Depend; 2007 Apr; 88(1):75-8. PubMed ID: 17055191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of psychotherapy attendance on buprenorphine treatment outcome.
    Montoya ID; Schroeder JR; Preston KL; Covi L; Umbricht A; Contoreggi C; Fudala PJ; Johnson RE; Gorelick DA
    J Subst Abuse Treat; 2005 Apr; 28(3):247-54. PubMed ID: 15857725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A dose-effect study of repeated administration of buprenorphine/naloxone on performance in opioid-dependent volunteers.
    Mintzer MZ; Correia CJ; Strain EC
    Drug Alcohol Depend; 2004 May; 74(2):205-9. PubMed ID: 15099664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Who benefits from additional drug counseling among prescription opioid-dependent patients receiving buprenorphine-naloxone and standard medical management?
    Weiss RD; Griffin ML; Potter JS; Dodd DR; Dreifuss JA; Connery HS; Carroll KM
    Drug Alcohol Depend; 2014 Jul; 140():118-22. PubMed ID: 24831754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medical treatment of opioid dependence within the South African context.
    Weich L
    SADJ; 2010 May; 65(4):168-71. PubMed ID: 20632700
    [No Abstract]   [Full Text] [Related]  

  • 20. Buprenorphine implants and opioid dependence.
    Rastegar DA
    JAMA; 2011 Jan; 305(3):253; author reply 254-5. PubMed ID: 21245178
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.